View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AI14 | Publication ID: Spring 2024 |
Title: Biologics Regulation Modernization | |
Abstract:
FDA’s biologics regulations will be updated to clarify existing requirements and procedures related to Biologic License Applications and to promote the goals associated with FDA’s implementation of the abbreviated licensure pathway created by the Biologics Price Competition and Innovation Act of 2009. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 601 | |
Legal Authority: 42 U.S.C. 262 21 U.S.C. 301, et seq. |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Mustafa Unlu Director of Policy Staff, Senior Policy Coordinator Department of Health and Human Services Food and Drug Administration 10903 New Hampshire Avenue, Building 22, Room 1139, Silver Spring, MD 20993 Phone:301 796-3396 Email: mustafa.unlu@fda.hhs.gov |